Baricitinib D4 (azetidine-2,2,4,4-d4)

Baricitinib D4 (azetidine-2,2,4,4-d4) is a deuterated form of the drug baricitinib. This drug is used to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Baricitinib D4 works by inhibiting Janus kinases (JAKs), which play a key role in the body’s immune response. By blocking JAKs, baricitinib D4 reduces inflammation and helps to alleviate the symptoms of these conditions. Baricitinib D4 is a small molecule drug that belongs to a class of compounds known as JAK inhibitors. It has a molecular formula of C16H13D4N7O and a molecular weight of 323.37 g/mol. The deuterated form of baricitinib is chemically identical to the non-deuterated form, except for the presence of four deuterium atoms. Baricitinib D4 is typically administered orally, in the form of tablets or capsules. The dosage and duration of treatment depends on the specific condition being treated and the severity of the symptoms. Patients should follow their doctor’s instructions carefully and report any side effects or changes in their condition promptly. Overall, baricitinib D4 is an effective and well-tolerated treatment option for a variety of inflammatory conditions. Its unique chemical properties make it a valuable tool for researchers studying the mechanisms of JAK inhibition and the immune system as a whole.